Best AAV / Gene Therapy CDMOs in Europe
35
CDMOs tracked
29
Fully scored
9
With FDA records
34
FDA inspections
166
EMA/MHRA GMP certs
2
Warning letters
For European-manufactured aav / gene therapy programs, Charles River Laboratories, ReciBioPharm, and FUJIFILM Diosynth Biotechnologies lead CDMO Signal's ranking of aav / gene therapy CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 56 scored aav / gene therapy CDMOs to 29 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.
Adeno-associated virus (AAV) is the dominant delivery platform for in vivo gene therapy, from rare-disease programs to larger systemic indications. Rising demand has pushed CDMOs to scale suspension processes and tighten full/empty capsid analytics.
Selecting an AAV CDMO hinges on serotype experience, suspension vs adherent platform, full/empty capsid separation, and a proven regulatory record. The rankings below score each manufacturer on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 11 NAI (no action), 22 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (42), Denmark (35), United States (28), Germany (17), Italy (13).
Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
91.7 | 98.7 | 8 insp · 11 GMP | Limited | 0 programs |
| 2 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 3 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
83.5 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 4 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
81.0 | 98.8 | 4 insp · 8 GMP | — | 0 programs |
| 5 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 6 |
TK
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 4 insp · 18 GMP | — | 100 programs |
| 7 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 8 |
PG
ProBioGen
Berlin, DE
|
78.9 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 9 |
XP
eXmoor Pharma
Bristol, United Kingdom
|
78.7 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 10 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 11 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 12 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 13 |
ET
Exothera
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 14 |
CE
Celonic
Basel, Switzerland
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 15 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 16 |
BV
Biovian
Turku, Finland
|
78.0 | 99.7 | 1 insp · 4 GMP | — | 0 programs |
| 17 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
77.1 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 18 |
VG
Viralgen Vector Core
San Sebastián, Spain
|
76.8 | 100.0 | 0 insp · 4 GMP | Available | 0 programs |
| 19 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
|
76.5 | 79.3 | 11 insp · 35 GMP | — | 0 programs |
| 20 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 21 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 22 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 23 |
RT
ReiThera
Rome, IT
|
71.1 | 100.0 | 0 insp · 4 GMP | — | 1 programs |
| 24 |
RA
Recipharm Advanced Bio
Stockholm, Sweden (US operations: Watertown, MA; EU/global ATMP division of Recipharm AB)
|
63.0 | — | — | — | 0 programs |
| 25 |
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
|
59.7 | — | — | — | 10 programs |
| 26 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 27 |
AM
Anemocyte
Gerenzano, IT
|
59.0 | — | — | — | 0 programs |
| 28 |
DINAMIQS
Schlieren (Zurich), Switzerland
|
59.0 | — | — | Available | 0 programs |
| 29 |
CV
CEVEC Pharmaceuticals
Cologne, DE
|
56.5 | — | — | — | 0 programs |
| — |
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
|
Profiled | — | — | — | 0 programs |
| — |
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
|
Profiled | — | — | — | 0 programs |
| — |
Spur Therapeutics
London, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Eppendorf BioBLU
Hamburg, Germany
|
Profiled | — | — | — | 0 programs |
| — |
IDT Biologika GmbH
Dessau-Roßlau, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
|
Profiled | — | — | — | 0 programs |
What to evaluate in a AAV / Gene Therapy CDMO
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
EMA and MHRA regulatory considerations for European-manufactured programs
European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.
QP release requirements and how they affect CDMO selection
Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.
Which European CDMOs also cover FDA (US) regulatory geography?
European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.
AAV / Gene Therapy CDMOs — Frequently Asked Questions
Who are the top AAV / Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked AAV / Gene Therapy CDMOs include Charles River Laboratories, ReciBioPharm, FUJIFILM Diosynth Biotechnologies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many AAV / Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 9 AAV / Gene Therapy CDMOs with FDA inspection records and 166 EMA/MHRA GMP certificates across the group.
What should I look for in an AAV CDMO?
Look for serotype experience, a scalable suspension platform, strong full/empty capsid analytics, and a clean FDA and EMA/MHRA record. Match validated bioreactor scale to your dose and indication.
What's the difference between AAV and lentiviral CDMOs?
AAV is non-integrating and produced at higher volumes for in vivo gene therapy. Lentivirus integrates into the genome, is made under BSL-2 with RCL testing, and is used mainly for ex vivo cell engineering like CAR-T.
Related modalities